Zydus Lifesciences Ltd

AI
Zydus Lifesci. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Zydus Lifesciences Ltd

₹ 1,190 -1.33%
13 Nov - close price
zyduscadila.com BSE: 532321 NSE: ZYDUSLIFE F&O
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

Business Segments:
a) North America Formulations (40% of Q4 FY26 revenue):
Co. ranked 3rd among US generic companies
by generic TRx, a gain of 2 positions over the
last 4 years. During Q4 FY26, 6 new products were launched, 3 ANDAs filed, and 9 ANDAs approved. For full year FY26, 30 ANDAs were filed and 26 approved including 6 tentative approvals. Cumulative filings stand at 508
and cumulative approvals at 435 including
26 tentative.[1]
b) India Formulations Business (24% of Q4 FY26 revenue):[2]
The company has 10 brands with value above Rs 1,000 mn, 24 between Rs 500-1,000 mn, and 35 between INR 250-500 mn. Key product launches in Q4 FY26 include Tishtha - world's first biosimilar of Nivolumab, Anyra - India's first indigenously developed biosimilar of Aflibercept 2 mg, and Semaglutide injection under three brands - Semaglyn, Mashema, and Alterme.
c) Consumer Wellness (20% of Q4 FY26 revenue):[3]
The company operates in 2 different segments viz. personal care segment comprising the Nycil and Everyuth brands and food and nutrition segment through the brands Glucon-D, Sugar Free, Complan, and Nutralite.[4]
Glucon-D holds ~59% market share (Rank 1), Nycil holds ~33% (Rank 1), Sugar Free holds ~96% (Rank 1). In the Everyuth range, Scrub holds ~49% share (Rank 1) and Peel Off holds ~75% (Rank 1), while Facial Cleansing holds ~8% (Rank 5). Complan holds 4% fat spread share (Rank 4). Nutralite is Rank 1 in fat spread by company estimates. RiteBite and Max Protein are Rank 1 in Nutrition & Protein Bar and Protein Cookies & Chips by company estimates.
d) International Markets Formulations (11% of Q4 FY26 revenue):
The company's international markets division comprises of the Emerging Markets (selected territories in Asia Pacific, Middle East, Africa and Latin America) and Europe (France, Spain and the UK). In emerging markets, co. adopted a focused, therapy led approach, tailoring the offerings to meet the needs of specific markets. In Europe, focus remains on broadening the portfolio and enhance the market coverage.

Website BSE NSE F&O
  • Market Cap ₹ 1,18,693 Cr.
  • Current Price ₹ 1,190
  • High / Low ₹ 1,267 / 836
  • Stock P/E 26.2
  • Book Value ₹ 279
  • Dividend Yield 0.08 %
  • ROCE 21.1 %
  • ROE 21.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 18.8% CAGR over last 5 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty Next 50

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
4,369 4,505 5,534 6,208 5,237 5,269 6,528 6,574 6,123 6,864 7,587 8,017 7,910
3,223 3,403 3,903 4,124 3,776 3,882 4,402 4,485 4,107 5,048 5,033 6,088 6,015
Operating Profit 1,146 1,102 1,630 2,084 1,461 1,388 2,126 2,088 2,016 1,816 2,554 1,929 1,894
OPM % 26% 24% 29% 34% 28% 26% 33% 32% 33% 26% 34% 24% 24%
53 60 160 63 68 57 -139 155 75 26 -263 126 159
Interest 9 20 35 32 25 32 77 85 101 130 123 156 187
Depreciation 184 195 205 215 234 229 238 238 302 360 508 530 604
Profit before tax 1,006 947 1,550 1,900 1,271 1,184 1,672 1,921 1,687 1,353 1,660 1,369 1,262
Tax % 22% 23% 21% 23% 29% 15% 25% 23% 27% 29% 19% 26% 26%
803 790 1,246 1,482 920 1,026 1,244 1,521 1,239 1,023 1,341 1,011 928
EPS in Rs 7.91 7.80 11.75 14.11 9.06 10.17 11.64 14.58 12.51 10.36 12.65 9.63 9.28
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
8,651 9,427 9,376 11,905 13,166 14,253 14,404 15,110 17,237 19,547 23,242 27,148 30,378
6,896 7,095 7,474 9,074 10,174 11,455 11,013 11,768 13,378 14,163 16,183 18,673 22,183
Operating Profit 1,756 2,332 1,902 2,831 2,991 2,798 3,391 3,342 3,860 5,384 7,058 8,475 8,195
OPM % 20% 25% 20% 24% 23% 20% 24% 22% 22% 28% 30% 31% 27%
45 112 127 111 183 -264 -231 2,581 -422 293 50 -7 48
Interest 68 53 45 91 194 342 159 127 130 81 166 439 596
Depreciation 287 292 373 539 599 696 670 713 723 764 916 1,408 2,002
Profit before tax 1,446 2,099 1,612 2,312 2,382 1,495 2,331 5,084 2,585 4,832 6,027 6,621 5,644
Tax % 18% 8% 8% 24% 22% 21% 8% 10% 23% 20% 23% 24%
1,188 1,964 1,517 1,810 1,899 1,204 2,185 4,618 2,092 3,973 4,673 5,124 4,302
EPS in Rs 11.24 18.89 14.53 17.35 18.06 11.49 20.84 43.83 19.37 38.36 44.97 50.09 41.92
Dividend Payout % 21% 17% 22% 20% 19% 30% 17% 6% 31% 8% 24% 2%
Compounded Sales Growth
10 Years: 11%
5 Years: 14%
3 Years: 16%
TTM: 24%
Compounded Profit Growth
10 Years: 11%
5 Years: 19%
3 Years: 32%
TTM: -10%
Stock Price CAGR
10 Years: 12%
5 Years: 20%
3 Years: 23%
1 Year: 26%
Return on Equity
10 Years: 20%
5 Years: 21%
3 Years: 21%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 102 102 102 102 102 102 102 102 101 101 101 101 100
Reserves 4,149 5,597 6,858 8,642 10,284 10,273 12,890 16,897 17,415 19,729 23,852 27,011 27,718
2,651 2,442 5,207 5,407 7,899 7,986 4,608 4,221 1,195 804 3,213 12,496 13,966
2,144 2,208 2,937 3,632 4,945 5,115 6,165 6,421 6,851 8,201 9,523 11,065 13,823
Total Liabilities 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 50,673 55,607
3,352 3,748 5,755 6,483 12,164 12,230 12,133 12,188 11,521 12,368 13,134 24,106 27,698
CWIP 798 951 1,543 1,527 837 742 783 726 1,201 2,423 2,692 3,698 1,636
Investments 154 416 435 746 674 765 830 3,288 1,547 1,220 6,412 7,540 8,348
4,743 5,235 7,371 9,028 9,556 9,740 10,019 11,439 11,294 12,822 14,451 15,328 17,925
Total Assets 9,047 10,350 15,104 17,783 23,231 23,477 23,765 27,642 25,562 28,834 36,689 50,673 55,607

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
994 1,894 1,312 919 1,282 2,932 3,294 2,104 2,689 3,196 6,781 2,117
-465 -860 -2,872 -974 -3,977 -1,004 -837 -1,018 1,542 -1,492 -8,363 -7,895
-351 -935 2,316 52 1,885 -1,528 -2,548 -868 -4,400 -1,779 1,995 5,807
Net Cash Flow 178 99 756 -3 -811 399 -90 219 -170 -75 414 28
Free Cash Flow 498 936 -1,623 -116 236 2,043 2,447 1,050 1,697 2,313 5,139 -530
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 79% 109% 81% 54% 65% 116% 107% 83% 85% 83% 122% 44%

Ratios

Consolidated / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 67 68 89 98 110 94 79 81 94 97 64 73
Inventory Days 175 158 193 211 208 207 246 245 197 202 227 282
Days Payable 125 154 165 167 149 152 168 141 123 125 131 142
Cash Conversion Cycle 118 71 116 142 169 149 158 185 168 175 160 212
Working Capital Days 6 -1 -34 17 10 -19 -6 20 70 88 3 -40
ROCE % 23% 28% 16% 18% 15% 11% 14% 13% 15% 22% 24% 21%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
US Formulations Sales
USD mn

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDA Approvals
count
Cumulative ANDA Filings
count
India Formulations Sales
INR mn
US Generics Market Rank
rank ・Standalone data
Consumer Wellness Sales
INR mn
International Markets Formulations Sales (EM + EU)
INR mn
India Formulations - Chronic and Sub-chronic Portfolio Share (MAT)
% ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
74.98% 74.98% 74.98% 74.98% 74.98% 75.00% 75.00% 75.00% 75.00% 75.00% 75.02% 75.01%
4.99% 5.72% 5.59% 7.52% 7.53% 7.31% 7.13% 7.34% 7.06% 6.95% 6.89% 7.05%
12.96% 12.55% 12.56% 10.59% 10.61% 10.95% 11.09% 10.86% 11.08% 11.20% 11.27% 11.28%
0.07% 0.07% 0.07% 0.05% 0.05% 0.05% 0.04% 0.00% 0.00% 0.00% 0.00% 0.00%
6.99% 6.66% 6.81% 6.85% 6.85% 6.69% 6.74% 6.81% 6.86% 6.86% 6.83% 6.66%
No. of Shareholders 3,06,4952,94,3243,36,3093,70,8633,65,3563,71,6193,86,1273,96,1054,03,2664,18,3143,99,2513,82,067

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls